{"url_path":"/sec/nrix/8-k/2026-07-09/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000038-index.html","accession_number":"0001549595-26-000038","cik":"0001549595","ticker":"NRIX","issuer_name":"Nurix Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000038-index.html","primary_entity_key":"0001549595","primary_entity_name":"Nurix Therapeutics, Inc."},"word_count":124,"has_tables":true,"body_markdown":"Item 2.02    Results of Operations and Financial Condition.\n\nOn July 9, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended May 31, 2026. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.\n\nThe information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing."}